SCHEMBL5445372

SCHEMBL5445372

CCc1c(Cl)nc2ccnn2c1Cl

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.43
KCNN3 Q9UGI6 11/20 0.39
KCNN1 Q92952 2/20 0.39
KCNN2 Q9H2S1 2/20 0.39
MAPKAPK2 P49137 2/20 0.39
CRHR1 P34998 2/20 0.37
CDK2 P24941 1/20 0.36
PRKAB2 O43741 1/20 0.34
PRKAG1 P54619 1/20 0.34
PRKAA2 P54646 1/20 0.34
PRKAA1 Q13131 1/20 0.34
PRKAG3 Q9UGI9 1/20 0.34
PRKAG2 Q9UGJ0 1/20 0.34
PRKAB1 Q9Y478 1/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
DPP4 P27487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8191475 0.85 PDE10A (0.42) PDE10AKCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL14013826 0.85 PDE10A (0.42) PDE10AKCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL4187704 0.80 PDE10A (0.41) PDE10AKCNN3KCNN1KCNN2PRKAB2
SCHEMBL311905 0.80 PDE10A (0.41) PDE10AKCNN3KCNN1KCNN2
SCHEMBL22978862 0.79 PDE10A (0.40) PDE10AKCNN3KCNN1KCNN2CRHR1
SCHEMBL4196336 0.79 PDE10A (0.40) PDE10AKCNN3KCNN1KCNN2DPP4
SCHEMBL3199721 0.79 PDE10A (0.40) PDE10AKCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL3198220 0.78 PDE10A (0.39) PDE10AKCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL1487743 0.77 PDE10A (0.47) PDE10AKCNN3KCNN1KCNN2MAPKAPK2
SCHEMBL1348660 0.74 KCNN3 (0.41) PDE10AKCNN3DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942900-B1 USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES MERCK SHARP & DOHME (US) 2015-06-03 EP disclosed
US-8211854-B2 Methods for inhibiting protein kinases SCHERING CORPORATION (US) 2012-07-03 US disclosed
US-8211854-B2 Methods for inhibiting protein kinases SCHERING CORPORATION (US) 2012-07-03 US disclosed
EP-1931676-B1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORP (US) 2011-11-16 EP disclosed
US-7776865-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2010-08-17 US disclosed
US-7776865-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2010-08-17 US disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 US disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 US disclosed
WO-2007044441-A2 USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION (US) 2007-04-19 WO disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 US disclosed
US-20070083044-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2007-04-12 US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 US disclosed
US-20070083044-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2007-04-12 US disclosed
WO-2007041712-A1 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2007-04-12 WO disclosed
US-20070027156-A1 Crf antagonists and heterobicyclic compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-01 US disclosed
EP-1666468-A1 CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 PDE10A 2927/4885KCNN3 3771/4885KCNN1 3717/4885
US-20070083044-A1 Pyrazolopyrimidines as protein kinase inhibitors CHEK1, CHEK2, BUB1 PDE10A 1963/4885KCNN3 3711/4885KCNN1 3601/4885
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES PIM1, AURKC, PIM3 PDE10A 2927/4885KCNN3 3771/4885KCNN1 3717/4885
US-20070027156-A1 Crf antagonists and heterobicyclic compounds CRHR2, CRHR1, CRH PDE10A 1476/4885KCNN3 1739/4885KCNN1 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.